Published: 2017-10-27

A psoriatic arthritis patient who developed hypertriglyceridemia while receiving adalimumab treatment

Filiz Mercantepe, Mehmet Serhat Topaloğlu, Murat Yildirim, Erdem Özkaya


Anti-TNF agents have prominent effect on inflammatory diseases and they probably have various effects on lipid metabolism. Adalimumab (ADA) is the first fully human TNF-alfa antagonist. Our study presents a male patient who developed evident hypertriglyceridemia while receiving ADA treatment. We retrospectively collected data of one psoriatic arthritis patient treated with adalimumab at the University Hospital of Recep Tayyip Erdogan (November 2016). Adalimumab treatment significantly increased triglyceride from 278mg/dl to 4046mg/dl. The influence of adalimumab treatment on lipid profile seems to be proatherogenic, but further investigation is needed to confirm this hypothesis.


Adalimumab, Etanercept, Hypertriglyceridemia, Psoriatic arthritis

Full Text:



Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1806-12.

Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181:S462-72.

Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semi Arthritis Rheum. 2004;34:585-92.

Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheum. 2006;33:2440-6.

Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Disco. 2003;2:52-62.

Sakthiswary R, Syahrul Sazliyana S, Mohd Shahrir MS, Shahril NS, Hussein H. Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices. EXCLI J. 2012;11:142-9.

Stinco G, Piccirillo F, Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Brit J Derma. 2007;157(6):1273-4.

Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, et al. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response. Drug Dev Res. 2014;75:77-80.

Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Aca Sci. 2006;1069:414-9.

Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Kl Wo. 2002;114:1004-7.

Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scan J Rheum. 2006;35:107-11.

Javot L, Pere P, Got I, Petitpain N, Peyrin-Biroulet L, Gillet P. Hypertrigyceridemia during infliximab therapy. Joint Bone Spine. 2014;81:94-6.

Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947-55.